L'Oréal has signed an agreement with Debut, a leader in biotech beauy.

Since insulin produced by genetically engineered bacteria—rather than the pancreases of slaughtered animals—was first approved in 1982, the market for ‘biomanufactured’ products produced by microbial, animal, or plant cells has grown rapidly. “But in areas other than pharma—whose business models are built on high-margin, low-volume products with low sensitivity to costs—innovations have created only niche markets in enzymes, fragrances, and food and feed supplements,” concedes a recent report from Synonym and Boston Consulting Group. So what will it take to make the economics of precision fermentation stack up for a wider range of bioproducts such that they can compete with low-margin, high volume products derived from petrochemicals or industrialized animal agriculture?

BOSTON--(BUSINESS WIRE)--SpringTide Ventures, a leader in early-stage HealthTech venture capital, today announced the successful close of its Fund II at $65 million, bringing its total assets under management to over $100 million. This new fund underscores the firm’s continued commitment to driving innovation and elevating health globally through investments in digital health, medical devices, life sciences, and tech-enabled care delivery."Fund II presents an exciting opportunity to deepen our impact on human health by partnering with entrepreneurs who are positively disrupting healthcare," said Austin Walters, Managing Partner at SpringTide Ventures. “This milestone is not just a reflection of our past successes but a testament to the commitment of our team, partners and founders to bring transformative solutions to market that enhance patient care, improve outcomes, and expand access to quality care."Noteworthy achievements from SpringTide Ventures’ portfolio include:GreatExpectations.io : The world’s leading data quality tooling company recently surpassed a rate of over 15 million downloads per month.: The world’s leading data quality tooling company recently surpassed a rate of over 15 million downloads per month. Pathology Watch : An end-to-end dermatopathology software platform, including AI interpretation; acquired by Sonic Healthcare in January 2024 for $150 million.: An end-to-end dermatopathology software platform, including AI interpretation; acquired by Sonic Healthcare in January 2024 for $150 million. Debut Biotech : A leading cell-free biomanufacturing company that launched its own skin care product line in 2023 and raised a $20 million Series B led by L’Oreal.A leading cell-free biomanufacturing company that launched its own skin care product line in 2023 and raised a $20 million Series B led by L’Oreal. OpenLoop: An end-to-end telemedicine enablement company surpassed $100 million in annualized revenues in early 2024."We are so proud of the extraordinary achievements of our current founders and partners and are inspired by their commitment to grow and scale," added Walters